Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Melanoma and Skin CancerFurther Publications Rheumatology

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma

J Autoimmun

Tenstad HB, Ruhlmann CH, Möller S, Kjaer S, Bastholt L, Just SA, Lindegaard H

doi: 10.1016/j.jaut.2025.103400

Melanoma and Skin Cancer

Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors

Melanoma Res

Janßen S, Moufarrej A, Springer R, Häberle L, Jäger P, Antke C, Homey B, Lindhof HH

doi: 10.1097/CMR.0000000000001028

Melanoma and Skin Cancer

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL)

Br J Dermatol

Nardin C, Cavalieri C, Lebbé C, Gérard E, Puyraveau M, Vergara R, Maubec E, Kramkimel N, Lesage C, Rouanet J, Bonniaud B, Puzenat E, Popescu D, Baroudjian B, Le Corre Y, Saiag P, Brunet Possenti F, Saint-Jean M, Montaudié H, Amini-Adle M, Belkaid S, Grange F, Mansard S, Béjar CL, Darras S, Pages C, Tournier E, Funck-Brentano E, Aubin F

doi: 10.1093/bjd/ljaf268

Further Publications Immunology

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Acta Derm Venereol

Juan-Carpena G, Martínez Banaclocha N, Palazón Cabanes JC, Niveiro-de Jaime M, Betlloch Mas I, Blanes-Martínez M

doi: 10.2340/actadv.v105.42023

Further Publications Rheumatology

Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis

Semin Arthritis Rheum

Cappelli LC, Perin J, Zeger S, Jones M, Bingham CO, Shah AA

doi: 10.1016/j.semarthrit.2025.152773

Melanoma and Skin Cancer

Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients

Ann Dermatol Venereol

David C, Coquelle C, Le Corre Y, L'Orphelin JM, Nardin C, Aubin F, Cassecuel J, Dreno B, Wierzbiecka-Hainault E, Bens G, Beneton N, Dinulescu M, Kervarrec T, Saiag P, Blom A, Samimi M

doi: 10.1016/j.annder.2025.103411

Melanoma and Skin Cancer

Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis

Melanoma Res

Davidson SJ, Teoh DGK, Dudek AZ, Vogel RI

doi: 10.1097/CMR.0000000000001036

Immunodeficiency

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

J Clin Immunol

Lumry WR, Palumbo M, Hsu C, Hussain I, McNeil D, Bridges T, Wedner HJ, Scarupa M, Mondou E, Nanaware-Kharade N, Hanna K, Coll MQ, Oliveras J

doi: 10.1007/s10875-025-01952-5

Melanoma and Skin Cancer

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Melanoma Res

Al-Naesan I, Krepper D, Sparano F, Sztankay M, Efficace F, Giesinger JM

doi: 10.1097/CMR.0000000000001014

Related content

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma

Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL)

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis

Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients

Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results